Use of Pembrolizumab Expanded to 13th Type of Cancer in Five Years

The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S. Food and Drug Administration (FDA) first approved the groundbreaking immunotherapeutic pembrolizumab (Keytruda). Since that September 2014 approval, for melanoma, pembrolizumab has been approved for use in the treatment of another 12 types of cancer, most recently endometrial cancer, and the treatment of any type of solid tumor that tests positive for either of two specific biomarkers, microsatellite instability–high or mismatch repair–deficient.

Read More

FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

FDA Approves First Immunotherapy-Companion Diagnostic Combo for Lung Cancer

On the heels of the U.S. Food and Drug Administration’s approval of a combination of immune checkpoint inhibitors for unresectable and metastatic melanoma comes yet another immunotherapy approval. This time …

Read More

New Immunotherapy Advances Presented at the AACR Annual Meeting 2015

Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals …

Read More

SABCS 2014: Immunotherapy Shows Early Promise for Triple-negative Breast Cancer Patients

After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope for women with a very challenging form of breast cancer—triple-negative breast …

Read More